Eli Lilly & Co., a global pharmaceutical company and one of the world's largest corporations. has informed that it has withdrawn its new-drug application to the U.S. Food & Drug Administration (USFDA) for Cymbalta.

The pharmaceutical firm plans to resubmit application in the first half of next calendar year with supplementary data from a recently completed study in chronic osteoarthritis pain of the knee.